Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 30;17(6):724.
doi: 10.3390/pharmaceutics17060724.

Mechanistic Insight into the Enhanced Anti-Pulmonary Hypertension Efficacy of Wogonin Co-Amorphous

Zhongshui Xie  1 , Yucai Chen  2 , Jiaqi Xie  1 , Yan Lei  1 , Chunxue Jia  1 , Yulu Liang  1 , Hongjuan Wang  1 , Jianmei Huang  1
Affiliations

Mechanistic Insight into the Enhanced Anti-Pulmonary Hypertension Efficacy of Wogonin Co-Amorphous

Zhongshui Xie et al. Pharmaceutics. .

Abstract

Background: Pulmonary hypertension (PH) remains a life-threatening rare disease characterized by inflammation and oxidative stress in pulmonary artery smooth muscle cells (PASMCs). Wogonin (Wog), a plant-derived polyphenolic compound extracted from Scutellaria baicalensis Georgi, exhibits notable antioxidant activity and anti-PH efficacy, whereas its clinical applications are greatly limited by poor aqueous solubility. Methods: Herein, an innovative wogonin-aloperine co-amorphous (Wog-Alop) was developed to improve the aqueous solubility and, thus, anti-PH efficacy of Wog. Results: As expected, the aqueous solubility of Wog-Alop is about 40-fold that of Wog; meanwhile, the Wog-Alop demonstrates better oral bioavailability and anti-PH efficacy than Wog; moreover, the Wog-Alop exhibits significantly enhanced capacity to attenuate oxidative stress in human PASMCs compared to Wog. Conclusions: The results suggested that Wog-Alop could not only improve the solubility of Wog, thereby enhancing its oral bioavailability but also alleviate Wog's oxidative stress effects. These synergistic effects ultimately culminate in the enhanced anti-PH efficacy of Wog. In summary, the present study developed an innovative co-amorphous strategy for the delivery of Wog and improved its anti-PH efficacy.

Keywords: co-amorphous; oxidative stress; pulmonary hypertension; solubility; wogonin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Preparation and characterization of Wog-Alop. (A) Preparation process of Wog-Alop; (B) PXRD patterns of wogonin, aloperine, Wog+Alop and Wog-Alop; (C) DSC patterns of wogonin, aloperine and Wog-Alop; (D) FTIR patterns wogonin, aloperine and Wog-Alop; (E) Stability of Wog-Alop in illumination, high humidity, high temperature (Alop: aloperine; Wog: wogonin; Wog+Alop: the physical mixture of wogonin and aloperine; Wog-Alop: Wogonin-aloperine co-amorphous).
Figure 2
Figure 2
In vitro dissolution (A) and solubility states (B) of Wog-Alop in water.
Figure 3
Figure 3
The dissolving process of insoluble drugs in aqueous environment.
Figure 4
Figure 4
In vivo pharmacokinetics of Wog-Alop.
Figure 5
Figure 5
Effect of Wog-Alop on hemodynamics and myocardial electrophysiology of rats from each group. (A) Schematic diagram of in vivo anti-PH efficacy experiments; (B) Effect of Wog-Alop on P-wave duration; (C) Effect of Wog-Alop on RVSP. Data are expressed as the mean ± SD, n = 6, ### p < 0.001 vs. control group, #### p < 0.0001 vs. control group; **** p < 0.0001 vs. model group, *** p < 0.001 vs. model group, ** p < 0.01 vs. model group.
Figure 6
Figure 6
Effect of Wog-Alop on the right ventricular remodeling of rats from each group. (A) Effect of Wog-Alop on right ventricular remodeling (40×); (B) Effect of Wog-Alop on RVMI; (C) Effect of Wog-Alop on RVHI. Data are expressed as the mean ± SD, n = 6, #### p < 0.0001 vs. control group; * p < 0.05 vs. model group.
Figure 7
Figure 7
Effect of Wog-Alop on pulmonary vascular remodeling of rats from each group. (A) Resorcinol basic fuchsin staining and PCNA immunofluorescence of lung tissues; (B) Effect of Wog-Alop on the medial wall thickness of small pulmonary artery vessels; (C) Effect of Wog-Alop on PCNA positive cells of lung tissue. Data are expressed as the mean ± SD, n = 6, ### p < 0.001 vs. control group, # p < 0.05 vs. control group, *** p < 0.001 vs. model group, * p < 0.05 vs. model group.
Figure 8
Figure 8
Effects of different drug treatments on abnormal proliferation and ROS in PDGF-BB-induced PASMCs. (A) Representative images of ROS levels in PDGF-BB-induced PASMCs; (B) Effects of 3 μM Wog, Alop, Wog+Alop (PM), and Wog-Alop (CAM) treatments on the abnormal proliferation of PDGF-BB-induced PASMCs; (C) Effects of 3 μM Wog, Alop, Wog+Alop (PM), and Wog-Alop (CAM) treatments on ROS levels in PDGF-BB-induced PASMCs (n = 3, ## p < 0.01 vs. Control group, ### p < 0.001 vs. Control group; * p < 0.05, ** p < 0.01 vs. Model group).
Figure 9
Figure 9
Effects of 3 μM Wog, Alop, Wog+Alop (PM), and Wog-Alop (CAM) treatments on MDA level (A), CAT activity (B), GPx activity (C), and GSH levels (D) in PDGF-BB-induced PASMCs (n = 3, ### p < 0.001 vs. Control group, #### p < 0.0001 vs. Control group; * p < 0.05 vs. Model group, ** p < 0.01 vs. Model group, *** p < 0.001 vs. Model group, **** p < 0.0001 vs. Model group).
See this image and copyright information in PMC

References

    1. Cueto-Robledo G., Tovar-Benitez D., Alfaro-Cruz A., Gonzalez-Hermosillo L.-M. Systemic Scleroderma: Review and Updated Approach and Case Description to Addressing Pulmonary Arterial Hypertension and Idiopathic Pulmonary Fibrosis: A Dual Challenge in Treatment. Curr. Probl. Cardiol. 2024;49:102404. doi: 10.1016/j.cpcardiol.2024.102404. - DOI - PubMed
    1. Pugliese S.C., Poth J.M., Fini M.A., Olschewski A., El Kasmi K.C., Stenmark K.R. The Role of Inflammation in Hypoxic Pulmonary Hypertension: From Cellular Mechanisms to Clinical Phenotypes. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015;308:L229–L252. doi: 10.1152/ajplung.00238.2014. - DOI - PMC - PubMed
    1. Chen J.N., Zhou R.D.P. On the Sign-Imbalance of Permutation Tableaux. Adv. Appl. Math. 2017;86:1–18. doi: 10.1016/j.aam.2016.11.012. - DOI
    1. Zimmer A., Teixeira R.B., Constantin R.L., Campos-Carraro C., Aparicio Cordero E.A., Ortiz V.D., Donatti L., Gonzalez E., Bahr A.C., Visioli F., et al. The Progression of Pulmonary Arterial Hypertension Induced by Monocrotaline Is Characterized by Lung Nitrosative and Oxidative Stress, and Impaired Pulmonary Artery Reactivity. Eur. J. Pharmacol. 2021;891:173699. doi: 10.1016/j.ejphar.2020.173699. - DOI - PubMed
    1. Yu W., Chen H., Yang H., Xia P., Zou C., Sun T., Wang L. rBMSC/Cav-1F92A Mediates Oxidative Stress in PAH Rat by Regulating SelW/14-3-3η and CA1/Kininogen Signal Transduction. Stem Cells Int. 2019;2019:6768571. doi: 10.1155/2019/6768571. - DOI - PMC - PubMed

LinkOut - more resources